Varmx raises €32 million in series b financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants

Varmx announces the completion of a €32 million series b financing round to develop innovative approaches for the reversal of anticoagulation.
KFS Ratings Summary
KFS Quant Ranking